Documents

Q1 FY 2027 saw 17% revenue growth and margin expansion, led by volume and specialty diagnostics.

Strong growth and margin expansion driven by specialty testing, technology, and network scale.

FY 2026 delivered strong revenue and margin growth, with Specialty and digital channels driving performance.

Strong Q3 revenue and margin growth, with bonus shares and strategic expansion initiatives.

23% revenue growth, margin expansion, and strong integration drive robust FY2026 outlook.

Strong Q1 growth, margin expansion, and successful integration of acquisitions drive outlook.

FY26 revenue growth guided at 25-26% with margin expansion and strong B2C momentum.

Q3 revenue up 11%, B2C at 55%, Core Diagnostics deal to boost EPS and specialty growth.

Double-digit revenue and profit growth driven by B2C, specialty, and tier 3/4 expansion.

Q1 FY25 revenue grew 13.1% year-over-year, with margins and profits rising even faster.

Acquisition of Core Diagnostics accelerates leadership in oncology diagnostics and national expansion.